Beta-hCG, CSF Quantitative (Tumor Marker)
| Abbrev Code: | HCGCSF | ||
| Order Code: | LAB6749 | Order Name: | Beta-hCG, CSF Quant Tumor Marker |
| Synonyms: | Beta hCG | ||
| Methodology: | Electrochemiluminescent immunoassay | ||
| CPT Codes: | 84702 x1 | ||
| Turnaround Time: | Specimens are sent to reference laboratory Mon-Sat; results are reported within 1 day. | ||
| Compliance: | For tests developed and validated by ARUP (previously referred to as Compliance Statement B, C or D). This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes. |
||
Collection Instructions
| Specimen: | CSF |
| Optimal Volume: | 0.5 mL |
| Minimum\Peds Volume: | 0.3 mL |
| Container: | Sterile tube Alternate Containers: Green (lithium heparin, no gel), Red (no gel) |
| Causes for Rejection: | Any other body fluid. |
Processing and Shipping
| Specimen Processing: | Do not process. Store in refrigerator. |
| Shipping Instructions: | Ship at refrigerated temperature. |
| Stability: | 5 days at room temperature; 2 weeks refrigerated; 1 year frozen. |
| Test Performed at or Referral Lab | Lab Sendouts (ARUP) |
| Referral Lab number: | 20730 |
Interpretive
| Reference Range: | 0-3 IU/L Reference range for patients less than 18 years of age is not provided by the reference laboratory. |
| Use: | Human chorionic gonadotropin (hCG) is a valuable aid in the management of patients with trophoblastic tumors, nonseminomatous testicular tumors, and seminomas when used in conjunction with information available from the clinical evaluation and other diagnostic procedures. Increased hCG concentrations have also been observed in melanoma, carcinomas of the breast, gastrointestinal tract, lung, and ovaries, and in benign conditions including cirrhosis, duodenal ulcer and inflammatory bowel disease. The result cannot be interpreted as absolute evidence of the presence or absence of malignant disease. The result in not interpretable as a tumor marker in pregnant females. |
Click HERE to Report test errors or omissions.
*If no email program is associated with this computer, please contact:
[email protected] for TestID: 5955"